442 related articles for article (PubMed ID: 16128885)
1. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.
van Dijk K; Fischer K; van der Bom JG; Grobbee DE; van den Berg HM
Haemophilia; 2005 Sep; 11(5):438-43. PubMed ID: 16128885
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
3. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
4. Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia.
Fischer K; van der Bom JG; Mauser-Bunschoten EP; Roosendaal G; Beek FJ; de Kleijn P; Grobbee DE; van den Berg HM
Thromb Haemost; 2000 Dec; 84(6):977-80. PubMed ID: 11154144
[TBL] [Abstract][Full Text] [Related]
5. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
6. Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis.
Olivieri M; Kurnik K; Pfluger T; Bidlingmaier C
Haemophilia; 2012 May; 18(3):369-74. PubMed ID: 22032268
[TBL] [Abstract][Full Text] [Related]
7. Progression of haemophilic arthropathy in children: a Lithuanian--Danish comparative study.
Saulyte Trakymiene S; Clausen N; Poulsen LH; Ingerslev J; Rageliene L
Haemophilia; 2013 Mar; 19(2):212-8. PubMed ID: 23167920
[TBL] [Abstract][Full Text] [Related]
8. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
9. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
10. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
Roosendaal G; Lafeber FP
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
[TBL] [Abstract][Full Text] [Related]
11. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
Taki M; Shirahata A
Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
[TBL] [Abstract][Full Text] [Related]
12. Is on-demand treatment effective in patients with severe haemophilia?
Aznar JA; Marco A; Jiménez-Yuste V; Fernández-Fontecha E; Pérez R; Soto I; Parra R; Moreno M; Mingot ME; Moret A;
Haemophilia; 2012 Sep; 18(5):738-42. PubMed ID: 22537601
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of joint damage in hemophilic children with early prophylaxis].
Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
[TBL] [Abstract][Full Text] [Related]
14. Utility of the Haemophilia Joint Health Score in study of episodically treated boys with severe haemophilia A and B in Lithuania.
Saulyte Trakymiene S; Ingerslev J; Rageliene L
Haemophilia; 2010 May; 16(3):479-86. PubMed ID: 20070384
[TBL] [Abstract][Full Text] [Related]
15. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands.
van Dijk K; Fischer K; van der Bom JG; Scheibel E; Ingerslev J; van den Berg HM
Br J Haematol; 2005 Jul; 130(1):107-12. PubMed ID: 15982352
[TBL] [Abstract][Full Text] [Related]
16. Intraarticular bleeding in children with hemophilia: the prevention of arthropathy.
Gregosiewicz A; Wośko I; Kandzierski G
J Pediatr Orthop; 1989; 9(2):182-5. PubMed ID: 2494223
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
[TBL] [Abstract][Full Text] [Related]
18. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
Nagel K; Walker I; Decker K; Chan AK; Pai MK
Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
[TBL] [Abstract][Full Text] [Related]
19. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
Berntorp E
Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
